Advanced searches left 3/3

Peginterferon Alfa-2b - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 07 August 2022

* If you want to update the article please login/register

A Prospective, Multicenter, Randomized Controlled Clinical Trial of Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in the Treatment of Adult Essential Thrombocythemia

This is a prospective, open-label, multicenter, controlled clinical trial between Interferon Alfa and Pegylated Interferon Alfa-2b in adult essential thrombocythemia. If Recombinant Interferon Alpha is not available, other interferons that have been listed can be used. Pegylated Interferon Alfa-2b, with an initial dose of 135 ug at week 0 and then 180 ug per week from week 1 to week 52, with a week from week 1 to week 52.

Source link: https://clinicaltrials.gov/ct2/show/NCT05395507

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions